Cite
786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma
MLA
R. Dummer, et al. “786O Tumor Biomarker Analysis from COLUMBUS Part 1: Encorafenib + Binimetinib for BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.” Annals of Oncology, vol. 33, Sept. 2022, p. S902. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1d17877fd86e66abefdbd69af971e187&authtype=sso&custid=ns315887.
APA
R. Dummer, N. Pathan, S. Deng, C. Robert, A.M. Arance Fernandez, J.W.B. de Groot, C. Garbe, H.J. Gogas, R. Gutzmer, I. Krajsova, G. Liszkay, C. Loquai, M. Mandala, D. Schadendorf, N. Yamazaki, A. di Pietro, T. Xie, P.A. Ascierto, & K. Flaherty. (2022). 786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma. Annals of Oncology, 33, S902.
Chicago
R. Dummer, N. Pathan, S. Deng, C. Robert, A.M. Arance Fernandez, J.W.B. de Groot, C. Garbe, et al. 2022. “786O Tumor Biomarker Analysis from COLUMBUS Part 1: Encorafenib + Binimetinib for BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.” Annals of Oncology 33 (September): S902. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1d17877fd86e66abefdbd69af971e187&authtype=sso&custid=ns315887.